Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Liabilities: 2024

Historic Other Non-Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 1 years, with Dec 2024 value amounting to $28.9 million.

  • Corvus Pharmaceuticals' Other Non-Current Liabilities was N/A to $3.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $3.8 million, marking a year-over-year change of. This contributed to the annual value of $28.9 million for FY2024, which is N/A change from last year.
  • Corvus Pharmaceuticals' Other Non-Current Liabilities amounted to $28.9 million in FY2024.
  • Corvus Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $28.9 million during FY2024, with a 5-year trough of $28.9 million in FY2024.
  • For the 1-year period, Corvus Pharmaceuticals' Other Non-Current Liabilities averaged around $28.9 million, with its median value being $28.9 million (2024).